Spatial transcriptomic analysis of primary and recurrent adult-type granulosa cell ovarian tumors identifies possible therapeutic targets

Spatial transcriptomic analysis of primary and recurrent adult-type granulosa cell ovarian tumors identifies possible therapeutic targets

Sarah McDonald
1,*
,
Khushi Ahuja
2
,
Chien-Wei Lin
2
,
Theresa A. Dlugi
1
,
Ishaque Pulikkal Kadamberi
1
,
Anjali Geethadevi
1
,
Pradeep Chaluvally-Raghavan
1
,
Elizabeth E. Hopp
1
*Correspondence to: Sarah McDonald, Department of Obstetrics and Gynecology, Medical College of Wisconsin, Milwaukee, WI 53226, USA. E-mail: sarahfmcdonald@gmail.com
EXO. 2026;1:202617. 10.70401/EXO.2026.0024
Received: May 15, 2026Accepted: November 16, 2026Published: November 17, 2026
Tips Icon
This manuscript is made available in its unedited form to allow early access to the reported findings. Further editing will be completed before final publication. As such, the content may include errors, and standard legal disclaimers are applicable.

Abstract

Background: Adult-type granulosa cell tumors (AGCT) are an uncommon ovarian cancer subtype. We used spatial transcriptomics to explore gene expression in tumor versus adjacent stromal cells within the tumor microenvironment (TME), and in primary versus recurrent tumors.

Methods: Four unmatched FFPE AGCT samples (two primary, two recurrent) were processed on the 10X Genomics Visium platform. Seurat clusters and STdeconvolution topics were annotated, followed by pathway enrichment and TME assessment by functional gene signatures. Primary and recurrent tumors were compared using pseudobulk and DESeq2. Tumor-stromal interactions were analyzed with SpatialCellChat, and trajectories with Monocle.

Results: Granulosa cells and fibroblasts were the most common cell types. These were subclassified into proliferative and steroidogenic granulosa cells, and myofibroblastic (myCAF), extracellular matrix (ECM-CAF), inflammatory (iCAF), and perivascular fibroblasts. MAPK, PI3K, and KRAS signaling were the most frequently enriched pathways. The TME was fibrotic and dominated by cancer-associated fibroblasts. SpatialCellChat highlighted the importance of the extracellular matrix and showed bidirectional tumor-stroma signaling. In total, 122 genes were upregulated in primary tumors and 33 were differentially expressed in recurrent tumors, including the steroidogenic enzyme CYP19A1, the receptor tyrosine kinases ERBB4 and RASGRF1, and stromal remodeling genes.

Conclusion: Spatial transcriptomics demonstrates hormonally active tumor regions and a fibrotic, CAF-dominant tumor microenvironment in AGCT. Several findings with potential translational significance could warrant further investigation.

Keywords

Spatial transcriptomics, granulosa cell tumors, tumor microenvironment, ovarian cancer

References

  • 1. Schumer ST, Cannistra SA. Granulosa cell tumor of the ovary. J Clin Oncol. 2003;21(6):1180-1189.
    [DOI] [PubMed]
  • 2. Färkkilä A, Haltia UM, Tapper J, McConechy MK, Huntsman DG, Heikinheimo M. Pathogenesis and treatment of adult-type granulosa cell tumor of the ovary. Ann Med. 2017;49(5):435-447.
    [DOI] [PubMed]
  • 3. Homesley HD, Bundy BN, Hurteau JA, Roth LM. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A gynecologic oncology group study. Gynecol Oncol. 1999;72(2):131-137.
    [DOI]
  • 4. Brown J, Shvartsman HS, Deavers MT, Ramondetta LM, Burke TW, Munsell MF, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors. Gynecol Oncol. 2005;97(2):489-496.
    [DOI]
  • 5. Burton ER, Brady M, Homesley HD, Rose PG, Nakamura T, Kesterson JP, et al. A phase II study of paclitaxel for the treatment of ovarian stromal tumors: An NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol. 2016;140(1):48-52.
    [DOI]
  • 6. Brown J, Brady WE, Schink J, Van Le L, Leitao M, Yamada SD, et al. Efficacy and safety of bevacizumab in recurrent sex cord-stromal ovarian tumors: Results of a phase 2 trial of the Gynecologic Oncology Group. Cancer. 2014;120(3):344-351.
    [DOI] [PubMed] [PMC]
  • 7. Ray-Coquard I, Harter P, Lorusso D, Dalban C, Vergote I, Fujiwara K, et al. Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal tumors: The ALIENOR/ENGOT-ov7 randomized clinical trial. JAMA Oncol. 2020;6(12):1923-1930.
    [DOI] [PubMed] [PMC]
  • 8. Banerjee SN, Tang M, O’Connell RL, Sjoquist K, Clamp AR, Millan D, et al. A phase 2 study of anastrozole in patients with oestrogen receptor and/progesterone receptor positive recurrent/metastatic granulosa cell tumours/sex-cord stromal tumours of the ovary: The PARAGON/ANZGOG 0903 trial. Gynecol Oncol. 2021;163(1):72-78.
    [DOI] [PubMed]
  • 9. Garcia-Donas J, Garrigos L, Lainez N, Santaballa A, Redondo A, Cueva JF, et al. Open-label phase II clinical trial of orteronel (TAK-700) in metastatic or advanced non-resectable granulosa cell ovarian tumors: The Greko II study (GETHI2013-01). Clin Transl Oncol. 2025;27(7):3223-3231.
    [DOI] [PubMed]
  • 10. Chae YK, Othus M, Patel SP, Wilkinson KJ, Whitman-Purves EM, Lea J, et al. SWOG/NCI phase II dual anti-CTLA-4/PD-1 blockade in rare tumors: Nonepithelial ovarian cancer. Clin Cancer Res. 2024;30(24):5593-5600.
    [DOI] [PubMed] [PMC]
  • 11. Shah SP, Köbel M, Senz J, Morin RD, Clarke BA, Wiegand KC, et al. Mutation of FOXL2 in granulosa-cell tumors of the ovary. N Engl J Med. 2009;360(26):2719-2729.
    [DOI]
  • 12. Pisarska MD, Bae J, Klein C, Hsueh AJW. Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene. Endocrinology. 2004;145(7):3424-3433.
    [DOI] [PubMed]
  • 13. Weis-Banke SE, Lerdrup M, Kleine-Kohlbrecher D, Mohammad F, Sidoli S, Jensen ON, et al. Mutant FOXL2C134W hijacks SMAD4 and SMAD2/3 to drive adult granulosa cell tumors. Cancer Res. 2020;80(17):3466-3479.
    [DOI] [PubMed] [PMC]
  • 14. Carles A, Trigo-Gonzalez G, Cao Q, Cheng SWG, Moksa M, Bilenky M, et al. The pathognomonic FOXL2 C134W mutation alters DNA-binding specificity. Cancer Res. 2020;80(17):3480-3491.
    [DOI]
  • 15. Khlebus E, Vuttaradhi VK, Welte T, Khurana N, Celestino J, Beird HC, et al. Comparative tumor microenvironment analysis of primary and recurrent ovarian granulosa cell tumors. Mol Cancer Res. 2023;21(5):483-494.
    [DOI] [PubMed] [PMC]
  • 16. Laga T, Van Rompuy AS, Busschaert P, Marquina G, Loverix L, Olbrecht S, et al. Single-cell profiling in ovarian germ cell and sex cord-stromal tumours. Br J Cancer. 2025;132(12):1110-1123.
    [DOI] [PubMed] [PMC]
  • 17. Khlebus EY, Vuttaradhi VK, Ferri-Borgogno S, Brodsky AL, Lawson BC, Mok SC, et al. Multiplexed imaging mass cytometry reveals tumor-immune microenvironment-dependent hormone receptor expression in adult-type ovarian granulosa cell tumors. Cancer Res Commun. 2025;5(10):1894-1909.
    [DOI] [PubMed] [PMC]
  • 18. Miller BF, Huang F, Atta L, Sahoo A, Fan J. Reference-free cell type deconvolution of multi-cellular pixel-resolution spatially resolved transcriptomics data. Nat Commun. 2022;13(1):2339.
    [DOI] [PubMed] [PMC]
  • 19. Hou W, Ji Z. Assessing GPT-4 for cell type annotation in single-cell RNA-seq analysis. Nat Methods. 2024;21(8):1462-1465.
    [DOI] [PubMed] [PMC]
  • 20. Bagaev A, Kotlov N, Nomie K, Svekolkin V, Gafurov A, Isaeva O, et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. Cancer Cell. 2021;39(6):845-865.e7.
    [DOI] [PubMed]
  • 21. Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2025;20(1):180-219.
    [DOI] [PubMed]
  • 22. Cao J, Spielmann M, Qiu X, Huang X, Ibrahim DM, Hill AJ, et al. The single-cell transcriptional landscape of mammalian organogenesis. Nature. 2019;566(7745):496-502.
    [DOI] [PubMed] [PMC]
  • 23. Murphy AE, Skene NG. A balanced measure shows superior performance of pseudobulk methods in single-cell RNA-sequencing analysis. Nat Commun. 2022;13(1):7851.
    [DOI] [PubMed] [PMC]
  • 24. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
    [DOI]
  • 25. Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, et al. Enrichr: A comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44(W1):W90-W97.
    [DOI] [PubMed] [PMC]
  • 26. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene Ontology: Tool for the unification of biology. Nat Genet. 2000;25(1):25-29.
    [DOI]
  • 27. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27-30.
    [DOI] [PubMed] [PMC]
  • 28. Milacic M, Beavers D, Conley P, Gong C, Gillespie M, Griss J, et al. The reactome pathway knowledgebase 2024. Nucleic Acids Res. 2024;52(D1):D672-D678.
    [DOI] [PubMed] [PMC]
  • 29. Liberzon A, Birger C, Thorvaldsdóttir H, Ghandi M, Mesirov JP, Tamayo P. The molecular signatures database hallmark gene set collection. Cell Syst. 2015;1(6):417-425.
    [DOI]
  • 30. Brink GJ, Groeneweg JW, van der Ploeg P, Jonges GN, Gort EH, Witteveen PO, et al. Signal transduction pathway activity in adult-type granulosa cell tumor samples. Gynecol Oncol. 2025;195:6-11.
    [DOI] [PubMed]
  • 31. Carver BS, Chapinski C, Wongvipat J, Hieronymus H, Chen Y, Chandarlapaty S, et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. Cancer Cell. 2011;19(5):575-586.
    [DOI] [PubMed] [PMC]
  • 32. Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452-4461.
    [DOI] [PubMed] [PMC]
  • 33. Qi W, Morales C, Cooke LS, Johnson B, Somer B, Mahadevan D. Reciprocal feedback inhibition of the androgen receptor and PI3K as a novel therapy for castrate-sensitive and-resistant prostate cancer. Oncotarget. 2015;6(39):41976-41987.
    [DOI] [PubMed] [PMC]
  • 34. Turner NC, Oliveira M, Howell SJ, Dalenc F, Cortes J, Moreno HLG, et al. Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med. 2023;388(22):2058-2070.
    [DOI] [PubMed] [PMC]
  • 35. Summey RM, Iden M, Tsaih SW, Schmidt R, Parashar D, Wang S, et al. Combination hormonal drug therapy inhibits in vitro growth of adult ovarian granulosa tumor cells. Cancer Invest. 2026;44(3):279-295.
    [DOI] [PubMed]

© The Author(s) 2026. This is an Open Access article licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Publisher’s Note

Science Exploration remains a neutral stance on jurisdictional claims in published maps and institutional affiliations. The views expressed in this article are solely those of the author(s) and do not reflect the opinions of the Editors or the publisher.

Share And Cite

Science Exploration Style
McDonald S, Ahuja K, Lin CW, Dlugi TA, Kadamberi IP, Geethadevi A, et al. Spatial transcriptomic analysis of primary and recurrent adult-type granulosa cell ovarian tumors identifies possible therapeutic targets. EXO. 2026;1:202617. https://doi.org/10.70401/EXO.2026.0024

Submit a Manuscript
Author Instructions
Cite this Article
Export Citation
Article Metrics
0
View
0
Download
Cited
Article Updates
Citation Icon Get citation